Management Team

Alison Moore was named President and CEO of Codexis in November 2025 after having served as Chief Technical Officer since September 2024 and as a director from 2020 to 2024. Dr. Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing. She is former Chief Technical Officer of Allogene Therapeutics, a pioneering clinical-stage, biotechnology company advancing CAR-T therapies. Prior to Allogene she spent a total of 20 years at Amgen, most recently as Senior Vice President, Process Development, including roles in Supply Chain and Manufacturing. Dr. Moore also has experience at Genentech as a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs. Dr. Moore holds a bachelor’s degree in Pharmacology with Honors and a PhD in Cell Biology from Manchester University, England.

Georgia Erbez is a seasoned financial and operations executive who joined Codexis as Chief Financial Officer in September 2024 and added the additional role of Chief Business Officer in November 2025. Prior to joining Codexis, she served as Chief Operating Officer at Walking Fish Therapeutics, a private B cell therapy company. Prior to that, she served as the Chief Financial Officer of Harpoon Therapeutics, a public T cell therapy company. Ms. Erbez held the role of Chief Business Officer and Chief Financial Officer at Zosano Pharma Corp., and has served as Chief Financial Officer for Revolution Medicines, Asterias Biotherapeutics and Raptor Pharmaceuticals. Earlier in her career, Ms. Erbez held senior positions in investment banking at Cowen and Company and Jefferies. In addition, she was a Managing Director at Axiom Financial Partners, a life-sciences consulting firm. She currently serves as a member of the board of directors of Coherus BioSciences. Ms. Erbez holds a bachelor’s degree in international relations with an emphasis on economics from the University of California, Davis.

Stefan Lutz joined Codexis in 2020 as the Senior Vice President of Research to lead the company’s research team advancing the discovery of proteins. Prior to his arrival in Redwood City, he was a Professor and Chair of the Chemistry Department at Emory University, having joined the university in 2002 and ascending to Chemistry Department Chair in 2014. In addition to his academic work, he has consulted for AgriMetis and served on the scientific advisory boards of ZuvaChem, CODA Genomics Inc. and SynBioX Inc. Stefan has co-authored more than 65 articles published in peer-reviewed journals and six technical books and journals. He holds six patents and is a frequent lecturer and speaker. Dr. Lutz received a BSc in chemistry/chemical engineering from the Zurich University of Applied Sciences, an MSc in Biotechnology from the University of Teesside and a PhD in chemistry from the University of Florida. He was a postdoctoral fellow at Pennsylvania State University.

Britton Jimenez joined Codexis in July 2024 and assumed responsibility for all commercial activities across RNA manufacturing and pharma biocatalysis. He previously served as Vice President, Global Partners with Catalent Pharma Solutions, overseeing all key strategic relationships and other leadership roles at Catalent from 2022-2023, and from 2012-2021. Prior to his most recent time at Catalent, Britton was Vice President of Business Development at Mayne Pharma, managing commercial activities and driving growth of their CDMO business, ultimately facilitating its $475M sale in 2022.

Throughout his career, Britton has demonstrated exceptional leadership in motivating teams, surpassing sales targets, and implementing innovative marketing strategies that fueled business growth. He consistently is ability to builds strong client relationships and executes his strategic vision strengthened to achieve and advance corporate our team and advanced our goals. Britton holds BA degrees from San Diego State University and California State University, Chico.

Ms. Frechou-Armijo is an accomplished human resources leader with over two decades of human resources experience, holding increasingly senior positions within life sciences and technology companies. Most recently, she served as Vice President, Human Resources at Cepheid, a molecular diagnostics company and part of the Danaher family of operating companies.  During her tenure, she led Cepheid’s workforce through rapid expansion and transformation, increasing employee headcount by greater than seven times over a five year period. Prior to Cepheid, Ms. Frechou-Armijo held senior Human Resource roles at Broadcom, where she led workforce strategy, change management and talent management. She also previously held human resources management roles with Molecular Devices, KPMG, and Genencor. She is known for leading through a culture of innovation, collaboration and continuous improvement. Ms. Frechou-Armijo received her BA from California State University, Chico.